September 2017

How Race Can Influence Care Goals and Treatment Decisions in Advanced Cancer

October 03, 2017

Partner Perspectives

An ongoing study found some differences by ethnicity regarding the importance of factors influencing treatment decisions at end of life, which reinforces the need for EOL communication to be tailored.

Helping Patients Manage Work-Life Balance During and After Treatment

September 28, 2017

Partner Perspectives

During and after treatment, the majority of patients will be back at their jobs sometime after diagnosis and treatment, but that doesn’t have to come with emotional distress if possible outcomes are discussed.

Two Late-Stage Trials Test Novel PI3K Inhibitor in Non-Hodgkin Lymphoma

September 22, 2017

Clinical Trials in Progress

Copanlisib (BAY 80-6946), a novel PI3K inhibitor, is being combined with standard rituximab (Rituxan)-based regimens in patients with relapsed, indolent non-Hodgkin lymphoma (NHL) in 2 phase III clinical trials that investigators hope will expand treatment options in refractory disease settings, particularly with less toxic alternatives.

CIPN Experienced by Many Patients Years After Treatment

September 22, 2017

Adverse Events Report

Ninety percent of patients with cancer may experience chemotherapy-induced peripheral neuropathy (CIPN) during treatment, and many will see this adverse effect long after treatment ends.

Proton Therapy: The New Weapon to Fight Cancer

September 11, 2017

Fast Facts for the Frontline

This precise radiation therapy allows physicians to treat patients with a wide range of cancers and with less potential for adverse effects than traditional radiation therapy.